Osteosarcoma Clinical Trial
Official title:
A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
Sarcomas are uncommon mesenchymal malignancies that encompass a variety of tumors of soft
tissue or bone. Included in this study are patients with osteosarcoma, Ewing sarcoma family
tumors, malignant fibrous histiocytoma, synovial sarcoma, leiomyosarcoma and fibrosarcoma.
Patients with these lesions presenting with metastatic disease remain largely incurable. In
all sarcomas, the lungs are by far the most frequent site of metastases.
There is a need for new therapies that have activity against these types of sarcomas.
REOLYSIN® is an unmodified oncolytic reovirus which replicates selectively in ras
transformed cells causing cell lysis. Activating mutations in ras or mutations in oncogenes
signaling through the ras pathway may occur in as many as 80% of human tumors. Such
mutations have been described in many of the common sarcomas of childhood and adults.
REOLYSIN® demonstrated excellent anti-tumor activity in vitro and in vivo in childhood
sarcoma cell lines.
Further supporting the development of REOLYSIN® in the context of sarcomas as detailed in
this study, is the fact that sarcomas resistant or refractory to conventional chemotherapy
may remain clinically responsive to viral therapy. Sarcoma patients with pulmonary
metastases may be especially suitable for studies with REOLYSIN® due to rapid selective
uptake of the virus by the lungs.
This Phase 2 study is designed to characterize the efficacy and safety of REOLYSIN® given
intravenously over 5 days every 4 weeks in patients with bone and soft tissue sarcomas
metastatic to the lung. Safety data, including laboratory parameters and adverse events,
will be collected for all patients in order to determine the toxicity and reversibility of
toxicity of REOLYSIN® therapy. Response will be assessed using radiographic imaging every 2
cycles of therapy.
OBJECTIVES:
1. To measure tumor responses and duration of response, and describe any evidence of
antitumor activity of intravenous multiple dose REOLYSIN® in patients with bone and
soft tissue sarcomas metastatic to the lung.
2. To evaluate safety of intravenous multiple dose REOLYSIN®.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
Completed |
NCT02383901 -
A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX
|
N/A | |
Active, not recruiting |
NCT01758666 -
A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy
|
N/A | |
Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
Completed |
NCT01615640 -
Diffusion Study on Patients With Osteosarcoma
|
||
Completed |
NCT00520936 -
A Study of Pemetrexed in Children With Recurrent Cancer
|
Phase 2 | |
Completed |
NCT00523419 -
Chemotherapy for Patients With Osteosarcoma
|
Phase 2 | |
Completed |
NCT00132158 -
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04319874 -
Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma
|
Phase 2 | |
Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
Recruiting |
NCT05642455 -
SPEARHEAD-3 Pediatric Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT06117878 -
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
|
Early Phase 1 | |
Not yet recruiting |
NCT04316091 -
A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma
|
Phase 1 | |
Recruiting |
NCT03932058 -
Proteomics Research of Osteosarcoma
|
||
Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Completed |
NCT00743496 -
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
|
Phase 1 | |
Recruiting |
NCT04040205 -
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
|
Phase 2 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03628209 -
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
|
Phase 1/Phase 2 |